OncoOne, founded by Randolf Kerschbaumer, PhD, Michael Thiele, PhD, and Alexander Schinagl, PhD, will advance various drug modalities aimed at targeting oxidized macrophage migration inhibitory factor (oxMIF), an isoform of macrophage migration inhibitory factor (MIF) recognized as a promising novel drug target for solid tumor cancer indications. Leveraging their extensive expertise in drug discovery and development, they established OncoOne with the mission to develop multiple proprietary drug modalities directed at oxMIF. Their objective is to swiftly progress into clinical trials for pancreatic, colorectal, lung, and ovarian cancers.